Provided is the use of an antagonist of type I interferon (IFN) in the manufacture of a composition for treating scleroderma in a patient in need of such treatment, wherein the antagonist is an anti-IFNaR antibody or an anti-IFNa antibody. Alleviated symptoms can be dermal fibrosis, skin lesions, alopecia, inflammation, dermal thickening, collagen deposition, proteinuria or complement deposition.
